Necrotizing enterocolitis (NEC) has long been treated as a single, monolithic disease—yet mounting evidence suggests it is anything but uniform. Clinically, NEC varies widely in onset timing, severity, and outcome. Mechanistically, that variability implies multiple distinct pathways to intestinal injury, even when infants present with similar symptoms and radiographic findings.
The trouble begins with the way NEC is diagnosed and staged. Traditional radiographic criteria and Bell staging were designed to standardize clinical decisions, but they cannot reliably separate biologically different forms of disease. As a result, clinicians may be applying the same risk assumptions and management strategies to patients whose underlying pathophysiology may actually diverge.
This limitation matters beyond bedside care. Research aimed at identifying biomarkers has struggled because the “NEC” label groups together potentially incompatible syndromes. When biologically distinct subtypes are pooled, molecular signals that might define a specific mechanism can become diluted, obscured by noise from other pathways.
In a 2026 Perspective in Pediatric Research, Garg and colleagues argue for abandoning the universal NEC label in favor of a data-driven, cluster-based taxonomy. Rather than treating NEC as one entity, the proposed approach uses clinical trajectories alongside multiomic measurements to identify reproducible subgroups.
A cluster-based framework could integrate how infants deteriorate over time with molecular features—such as host inflammatory programs, microbial signatures, and metabolic or genomic patterns captured across relevant datasets. Importantly, the goal is not simply to reclassify for convenience, but to connect subtypes to mechanisms that can be measured and tested.
Mechanism-informed diagnosis could then enable more tailored interventions. Instead of assuming that one therapeutic strategy fits all NEC presentations, clinicians could match treatment intensity or supportive regimens to the biology driving intestinal injury in each subgroup.
For clinical trials, the implications are equally significant. Trials that enroll heterogeneous populations risk washing out treatment effects because responders and non-responders may be distributed across mechanistic categories. Subtyping via multiomic clustering would allow trials to test therapies in more biologically coherent cohorts.
Ultimately, this shift could lead to earlier detection, more precise prognostication, and better selection of endpoints tied to specific mechanisms. For the most vulnerable neonatal patients, a move from staging alone to mechanistic classification may represent a practical step toward transforming NEC from a broad label into a set of actionable diagnoses.
Subject of Research: Necrotizing enterocolitis (NEC) as a paradigm shift
Article Title: “Necrotizing enterocolitis”: a paradigm shift.
Article References: Garg, P.M., Shenberger, J., Martin, C.R. et al. “Necrotizing enterocolitis”: a paradigm shift. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05303-x
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41390-026-05303-x
Keywords: Necrotizing enterocolitis; biomarkers; multiomics; cluster-based taxonomy; clinical trajectories
